| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Oxytocin receptor (OTR) – Kd = 9.5 nM (determined by radioactive binding competition assays, cited from Brown et al., 2010) [2]
Vasopressin V₁A receptor – Kd >1000 nM [2] Vasopressin V₁B receptor – Kd >1000 nM [2] Vasopressin V₂ receptor – Kd >1000 nM [2] Oxytocin receptor (OTR). PF-3274167 is a potent, selective, high-affinity non-peptide oxytocin receptor antagonist. It has a Ki of 9.5 nM for the oxytocin receptor. The compound shows excellent selectivity versus vasopressin receptors V1A (Ki = 1,120 nM) and V2 (Ki = 10,000 nM). Oxytocin receptors are G-protein-coupled receptors involved in various physiological processes including social behavior, stress response, and reproductive functions. |
|---|---|
| ln Vitro |
PF-3274167 is a selective and high-affinity nonpeptide antagonist of oxytocin receptor (OTR) with Ki of 9.5nM. PF-3274167 displayed promising in vivo pharmacokinetics and significantly improved aqueous solubility over related compounds containing a biaryl substituent. Oxytocin receptor is a G protein-coupled receptor/protein which functions as receptor for the hormone and neurotransmitter oxytocin. Oxytocin receptors are also present in the central nervous system.
Kinase Assay: PF-3274167 is a selective and high-affinity nonpeptide antagonist of oxytocin receptor (OTR) with Ki of 9.5nM. Cell Assay: In vitro, PF-3274167 binds to the oxytocin receptor with a Ki of 9.5 nM. It shows excellent selectivity versus vasopressin receptors, with almost no affinity for V1b and V1a subtypes. The compound inhibits signaling between G-protein-coupled receptors and G proteins. PF-3274167 displayed significantly improved aqueous solubility over related compounds. |
| ln Vivo |
PF-3274167 displayed promising in vivo pharmacokinetics and significantly improved aqueous solubility over related compounds containing a biaryl substituent. Oxytocin receptor is a G protein-coupled receptor/protein which functions as receptor for the hormone and neurotransmitter oxytocin. Oxytocin receptors are also present in the central nervous system.
In vivo, PF-3274167 is orally active and centrally permeable. It shows promising in vivo pharmacokinetics and can inhibit physiological ejaculation in rodents. The compound has good pharmacokinetics in rats. These in vivo properties support its potential for research on various disorders, including inflammatory disorders, autoimmune diseases, and cancer. |
| Enzyme Assay |
The oxytocin receptor binding assay for PF-3274167 typically involves radioligand binding studies using membranes from cells expressing the oxytocin receptor. Competition binding experiments are performed with varying concentrations of PF-3274167 and a radiolabeled oxytocin receptor ligand (e.g., [³H]-oxytocin or a labeled OTR antagonist). Nonspecific binding is determined in the presence of excess unlabeled oxytocin or a selective OTR antagonist. Ki values are calculated from competition binding curves. Selectivity is assessed by testing against vasopressin V1A and V2 receptors.
|
| Cell Assay |
Cells expressing the oxytocin receptor (e.g., recombinant cell lines or cells naturally expressing OTR) are used for functional assays. Cells are pre-incubated with varying concentrations of PF-3274167, followed by stimulation with an oxytocin receptor agonist (e.g., oxytocin). OTR activation is measured by calcium mobilization (using fluorescent calcium indicators), inhibition of forskolin-stimulated cAMP accumulation, or other second messenger assays. IC₅₀ or Ki values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo studies of PF-3274167 typically involve rodent models. The compound is administered orally or intraperitoneally at various doses. For pharmacokinetic studies, blood and brain samples are collected at various time points to measure compound concentrations. For efficacy studies, the compound is tested in models relevant to oxytocin receptor function, such as models of ejaculation, social behavior, or stress response.
|
| ADME/Pharmacokinetics |
PF-3274167 is orally active with good pharmacokinetics in rats. It has a molecular weight of 419.84 g/mol and a molecular formula of C₁₉H₁₉ClFN₅O₃. The compound is centrally permeable and shows significantly improved aqueous solubility over related compounds. These properties support its use in CNS research. Detailed human pharmacokinetic parameters are not extensively published.
|
| Toxicity/Toxicokinetics |
Detailed toxicology data for PF-3274167 are limited in publicly available sources. As an oxytocin receptor antagonist, the compound would have undergone standard preclinical safety evaluation. The compound's selectivity for OTR over vasopressin receptors suggests a favorable safety profile. In preclinical studies, the compound was well-tolerated.
|
| References |
Bioorg Med Chem Lett.2010 Jan 15;20(2):516-20.J Med Chem.2015 Mar 12;58(5):2547-52
|
| Additional Infomation |
PF-3274167 (compound 3 in reference 2) is a potent and selective oxytocin receptor antagonist. Its high affinity (Kd = 9.5 nM) and excellent selectivity over vasopressin receptors make it a valuable tool for developing fluorescent probes for time‑resolved FRET binding assays. The fluorescent derivatives (compounds 17‑20) derived from PF-3274167 retained high OTR affinity and selectivity, with Kd values ranging from 1.37 to 2.05 nM. [2]
PF-3274167 (Cligosiban) is a potent, selective, high-affinity non-peptide oxytocin receptor antagonist with a Ki of 9.5 nM. It shows excellent selectivity versus vasopressin receptors. PF-3274167 is orally active, highly selective, and centrally permeable. It has a molecular formula of C₁₉H₁₉ClFN₅O₃ and a molecular weight of 419.84 g/mol. The compound can be used for research on various disorders, including inflammatory disorders, autoimmune diseases, and cancer. |
| Molecular Formula |
C19H19CLFN5O3
|
|
|---|---|---|
| Molecular Weight |
419.84
|
|
| Exact Mass |
419.116
|
|
| CAS # |
900510-03-4
|
|
| Related CAS # |
|
|
| PubChem CID |
11683187
|
|
| Appearance |
Off-white to pink solid powder
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
584.0±60.0 °C at 760 mmHg
|
|
| Flash Point |
307.0±32.9 °C
|
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
|
| Index of Refraction |
1.646
|
|
| LogP |
1.85
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
8
|
|
| Rotatable Bond Count |
7
|
|
| Heavy Atom Count |
29
|
|
| Complexity |
532
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
HNIFCPBQMKPRCX-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C19H19ClFN5O3/c1-27-11-17-23-24-19(26(17)13-4-6-18(28-2)22-8-13)25-9-14(10-25)29-16-5-3-12(21)7-15(16)20/h3-8,14H,9-11H2,1-2H3
|
|
| Chemical Name |
5-[3-[3-(2-chloro-4-fluorophenoxy)azetidin-1-yl]-5-(methoxymethyl)-1,2,4-triazol-4-yl]-2-methoxypyridine
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (7.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (7.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (7.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3819 mL | 11.9093 mL | 23.8186 mL | |
| 5 mM | 0.4764 mL | 2.3819 mL | 4.7637 mL | |
| 10 mM | 0.2382 mL | 1.1909 mL | 2.3819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA